Evidence map›Paper›PMID 40543241›Full record

ArticleCancer epidemiology2025

Comorbidity burden and risk of second primary non-breast cancer in breast cancer survivors.

Amrita Mukherjee, Zheng Gu, Lie Hong Chen, Rowan T Chlebowski, Arnold L Potosky, Reina Haque

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amrita MukherjeeKaiser Permanente Southern California, Department of Research & Evaluation, Pasadena, CA, USA.
Zheng GuKaiser Permanente Southern California, Department of Research & Evaluation, Pasadena, CA, USA.
Lie Hong ChenKaiser Permanente Southern California, Department of Research & Evaluation, Pasadena, CA, USA.
Rowan T ChlebowskiLundquist Research Institute, Harbor-UCLA Medical Center, Torrance, CA, USA.
Arnold L PotoskyCancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington D.C., USA; Kaiser Permanente Bernard J. Tyson School of Medicine, Department of Health Systems Science, Pasadena, CA, USA.
Reina HaqueKaiser Permanente Southern California, Department of Research & Evaluation, Pasadena, CA, USA; Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington D.C., USA; Kaiser Permanente Bernard J. Tyson School of Medicine, Department of Health Systems Science, Pasadena, CA, USA. Electronic address: Reina.Haque@kp.org.

Funding

Risk prediction of breast cancer treatment-related cardiotoxicity to guide clinical decision makingR01HL154319 · NHLBI · KAISER FOUNDATION RESEARCH INSTITUTE · PI HAQUE, REINA, POTOSKY, ARNOLD L · 2020 to 2023
$1.5M
NHLBI NIH HHS R01 HL154319
6 · The paper itself

Abstract

backgroundBreast cancer survivors have an increased risk of second primary cancers. However, the impact of comorbidity burden on risk of second primary non-breast cancer in breast cancer survivors is under-studied. We evaluated the association of comorbidity burden with risk of second primary non-breast cancer in breast cancer survivors.

methodsIn this retrospective cohort study, breast cancer patients aged ≥ 18 years diagnosed with in-situ, local, or regional first primary breast between 2008 and 2020 at Kaiser Permanente Southern California, were included. Patients were followed until 12/31/2021. Rates of second primary non-breast cancer were reported. Association of Elixhauser comorbidity index (ECI) and second primary cancer was reported using Cox proportional hazards regression.

resultsOf 37,222 female breast cancer survivors included, 1701 (4.6 %) survivors developed second primary non-breast cancers during a median (interquartile range) follow-up of 5.2 (2.8-8.6) years. Nearly one-third (32.3 %) of the survivors had ECI score 3 + ; 22.6 % had ECI score 1-2; rest 27.0 % had zero ECI score. Incidence rates of second cancers were 561, 739, and 1064 per 100,000 person-years in survivors with ECI= 0, 1-2, and 3 + , respectively. In multivariable analyses, compared to survivors with ECI= 0, survivors with ECI scores 1-2 and 3 + had higher risk of second primary non-breast cancer [unadjusted HR (95 % CI): 1.32 (1.16-1.50) and 1.88 (1.65-2.14), respectively]. Higher risk of second primary non-breast cancer persisted in survivors with ECI score 3 + in the adjusted model [adjusted HR (95 % CI): 1.24 (1.08-1.43)].

conclusionComorbidity burden appears to be correlated with an increased risk of second primary non-breast cancers in breast cancer survivors. Active surveillance and effective management of modifiable comorbidities may help in reducing second primary cancer risk in breast cancer survivors.

Indexed as

Breast NeoplasmsCancer SurvivorsNeoplasms, Second PrimaryAdultAgedCaliforniaComorbidityFemaleFollow-Up StudiesHumansMiddle AgedRetrospective StudiesRisk FactorsBreast cancerCancer riskCancer survivorsComorbidity burdenSecond primary cancer

Identifiers

PMID40543241
PMCPMC12303378

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.